Ranelic Acid

Ranelic Acid

SCHEMBL500994

N#Cc1c(N(CC(=O)O)CC(=O)O)sc(C(=O)O)c1CC(=O)O

nearest known ligand 0.37

Full drug profile on Sugi Atlas →

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
FNTA P49354 8/20 0.37
FNTB P49356 8/20 0.37
GRIA4 P48058 3/20 0.35
GRIA2 P42262 2/20 0.35
PLA2G1B P04054 1/20 0.32
ATG4B Q9Y4P1 1/20 0.32
KMT2A Q03164 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ranelic Acid SCHEMBL1289746 1.00 FNTA (0.37) FNTAFNTBGRIA4GRIA2PLA2G1B
Ranelic Acid SCHEMBL8641592 0.98 FNTA (0.36) FNTAFNTBGRIA4GRIA2PLA2G1B
Ranelic Acid SCHEMBL2227556 0.98 FNTA (0.36) FNTAFNTBGRIA4GRIA2PLA2G1B
Ranelic Acid SCHEMBL2549310 0.98 FNTA (0.36) FNTAFNTBGRIA4GRIA2PLA2G1B
Ranelic Acid SCHEMBL15875995 0.98 FNTA (0.36) FNTAFNTBGRIA4GRIA2PLA2G1B
SCHEMBL14457745 0.93 GRIA4 (0.37) FNTAFNTBGRIA4GRIA2PLA2G1B
SCHEMBL14473856 0.91 FNTA (0.33) FNTAFNTBGRIA4GRIA2
Ranelic Acid SCHEMBL2511382 0.89 FNTA (0.34) FNTAFNTBGRIA4GRIA2
Ranelic Acid SCHEMBL15875990 0.87
Ranelic Acid SCHEMBL8641585 0.87

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 485 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117051245-A Method for recycling valuable elements in metallurgical waste residues 西安建筑科技大学 2023-11-14 CN claimed
EP-2756841-B1 Pharmaceutical compositions comprising an acid salt GALENICUM HEALTH SL (ES) 2015-05-13 EP claimed
US-9016221-B2 Surface topographies for non-toxic bioadhesion control UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) 2015-04-28 US claimed
US-20130310573-A1 PROCESS FOR THE PREPARATION OF STRONTIUM RANELATE DIVI'S LABORATORIES LIMITED (IN) 2013-11-21 US claimed
US-8569514-B1 Process for the preparation of strontium ranelate Divi's Laboratories, Ltd. (IN) 2013-10-29 US claimed
WO-2013113319-A1 PROCESS FOR THE PREPARATION OF STRONTIUM RANELATE, INTERMEDIATE OR HYDRATES THEREOF PHARMATHEN S.A. (GR) 2013-08-08 WO claimed
EP-2542546-A1 PROCESS FOR THE PREPARATION OF A POLYMORPH OF STRONTIUM RANELATE Chemelectiva Srl. (IT) 2013-01-09 EP claimed
EP-2523947-A1 PROCESS FOR THE PREPARATION OF STRONTIUM RANELATE Richter Gedeon Nyrt. (HU) 2012-11-21 EP claimed
US-8268352-B2 Modified release composition for highly soluble drugs TORRENT PHARMACEUTICALS LIMITED (IN) 2012-09-18 US claimed
US-8263125-B2 Dosage form for high dose-high solubility active ingredients that provides for immediate release and modified release of the active ingredients TORRENT PHARMACEUTICALS LIMITED (IN) 2012-09-11 US claimed
WO-2005108339-A2 HIGH YIELD AND RAPID SYNTHESES METHODS FOR PRODUCING METALLO-ORGANIC SALTS OSTEOLOGIX A/S (DK) 2005-11-17 WO claimed
EP-1403264-B1 Process for the industrial synthesis of 5-amino-3-carboxymethyl-4-cyano-2-thiophenecarboxydimethylester SERVIER LAB (FR) 2004-12-29 EP claimed
WO-2004098618-A2 STRONTIUM COMBINATIONS FOR PROPHYLAXIS/TREATMENT OF CARTILAGE AND/OR BONE CONDITIONS OSTEOLOGIX A/S (DK) 2004-11-18 WO claimed
WO-2004098617-A2 CONTROLLED RELEASE COMPOSITION CONTAINING A STRONTIUM SALT OSTEOLOGIX A/S (DK) 2004-11-18 WO claimed
US-20040059134-A1 Process for the industrial synthesis of tetraesters of 5-[BIS(CARBOXYMETHYL)AMINO]-3-carboxymethyl-4-cyano-2-thiophenecarboxylic acid, and application to the synthesis of bivalent salts of ranelic acid and their hydrates LES LABORATOIRES SERVIER (FR) 2004-03-25 US claimed
US-20040059135-A1 Process for the industrial synthesis of the methyl diester of 5-amino-3-carboxymethyl-4-cyano-2-thiophenecarboxylic acid, and application to the synthesis of bivalent salts of ranelic acid and their hydrates LES LABORATOIRES SERVIER (FR) 2004-03-25 US claimed
EP-1336602-A1 Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases Scaramuzzino, Giovanni (IT) 2003-08-20 EP claimed
EP-0813869-B1 Use of strontium salts for the treatment of arthritis SERVIER LAB (FR) 2003-03-05 EP claimed
EP-0415850-B1 Bivalent metal salts of 2-N,N-di(carboxymethyl)amino,3-cyano,4-carboxymethyl,5-carboxy-thiophene-acid, process for their preparation and pharmaceutical compositions containing them ADIR (FR) 1994-01-12 EP claimed
US-5128367-A Osteoporosis ADIR ET COMPAGNIE (FR) 1992-07-07 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040059135-A1 Process for the industrial synthesis of the methyl diester of 5-amino-3-carboxymethyl-4-cyano-2-thiophenecarboxylic acid, and application to the synthesis of bivalent salts of ranelic acid and their hydrates CA7, CA2, SLC38A7 FNTA 2847/4885FNTB 3509/4885GRIA4 1008/4885
US-20130310573-A1 PROCESS FOR THE PREPARATION OF STRONTIUM RANELATE HDHD5, HPSE, DHX35 FNTA 4515/4885FNTB 4847/4885GRIA4 1962/4885
US-20040059134-A1 Process for the industrial synthesis of tetraesters of 5-[BIS(CARBOXYMETHYL)AMINO]-3-carboxymethyl-4-cyano-2-thiophenecarboxylic acid, and application to the synthesis of bivalent salts of ranelic acid and their hydrates CA7, SLC6A6, CA6 FNTA 3614/4885FNTB 3445/4885GRIA4 1280/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.